Oraderm Pharmaceuticals

Oraderm Pharmaceuticals is an Australian specialty pharmaceutical company focused on the dermatology market, specifically the treatment of acne. Established as a joint venture between New Zealand's Douglas Pharmaceuticals and Zelira Therapeutics, the company leverages the manufacturing and registration expertise of its parents to commercialize dermatological products in the Australasian region. Its flagship product is Oratane, a widely prescribed brand of isotretinoin used for severe or recalcitrant acne. The company also explores innovative therapeutic avenues, including the potential application of cannabinoid-based research in dermatology. Oraderm maintains a strong presence in the Australian healthcare landscape by providing specialized formulations to dermatologists and patients.